VYNE Therapeutics reports Q2 results, evaluates pipeline opportunities.
ByAinvest
Thursday, Aug 14, 2025 8:07 am ET1min read
VYNE--
VYNE Therapeutics Inc. (Nasdaq: VYNE), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for chronic inflammatory and immune-mediated conditions, reported its second-quarter (Q2) 2025 financial results on August 14, 2025. The company ended the quarter with $39.6 million in cash, extending its runway into the first half of 2027 [1].
Key highlights of the Q2 financial report include a net loss of $5.8 million, down from $9.4 million in the same period last year, and a significant reduction in research and development (R&D) expenses. R&D expenses for the quarter ended June 30, 2025, were $4.9 million, a 33.2% decrease from $7.3 million in the same period in 2024. This reduction was primarily driven by decreased expenses for repibresib and VYN202, the company's topical and oral BET inhibitors, respectively [1].
VYNE's oral BD2-selective BET inhibitor, VYN202, has shown promising efficacy in a Phase 1b clinical trial for moderate to severe plaque psoriasis. The company also reported disease-modifying potential across multiple translational models of fibro-inflammatory diseases and hematologic malignancies. These findings underscore the therapeutic potential of VYN202 in areas such as nephrology, pulmonology, rheumatology, and myeloproliferative neoplasms [1].
The FDA partially lifted a clinical hold on VYN202, allowing female enrollment while requiring additional toxicology data for male subjects. However, the company's topical BET inhibitor, repibresib, missed primary endpoints in a Phase 2b vitiligo trial, leading to its termination. VYNE is now seeking a development partner for repibresib [1].
VYNE has implemented cost reductions that are expected to extend its cash runway into the first half of 2027, providing additional flexibility during this period. The company is actively evaluating opportunities to enhance the value of its pipeline programs [1].
References
[1] https://www.stocktitan.net/news/VYNE/vyne-therapeutics-reports-2025-second-quarter-financial-results-and-5mmdapji5gol.html
[2] https://www.globenewswire.com/news-release/2025/08/14/3133434/0/en/VYNE-Therapeutics-Reports-2025-Second-Quarter-Financial-Results-and-Provides-Business-Update.html
• VYNE Therapeutics reports Q2 financial results • Evaluating opportunities to enhance pipeline programs • VYN202 shows promising efficacy in psoriasis trial • Disease-modifying potential in fibro-inflammatory and hematologic malignancies • Therapeutic potential in nephrology, pulmonology, rheumatology, and myeloproliferative neoplasms.
Title: VYNE Therapeutics Reports Q2 Financial Results and Pipeline UpdatesVYNE Therapeutics Inc. (Nasdaq: VYNE), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for chronic inflammatory and immune-mediated conditions, reported its second-quarter (Q2) 2025 financial results on August 14, 2025. The company ended the quarter with $39.6 million in cash, extending its runway into the first half of 2027 [1].
Key highlights of the Q2 financial report include a net loss of $5.8 million, down from $9.4 million in the same period last year, and a significant reduction in research and development (R&D) expenses. R&D expenses for the quarter ended June 30, 2025, were $4.9 million, a 33.2% decrease from $7.3 million in the same period in 2024. This reduction was primarily driven by decreased expenses for repibresib and VYN202, the company's topical and oral BET inhibitors, respectively [1].
VYNE's oral BD2-selective BET inhibitor, VYN202, has shown promising efficacy in a Phase 1b clinical trial for moderate to severe plaque psoriasis. The company also reported disease-modifying potential across multiple translational models of fibro-inflammatory diseases and hematologic malignancies. These findings underscore the therapeutic potential of VYN202 in areas such as nephrology, pulmonology, rheumatology, and myeloproliferative neoplasms [1].
The FDA partially lifted a clinical hold on VYN202, allowing female enrollment while requiring additional toxicology data for male subjects. However, the company's topical BET inhibitor, repibresib, missed primary endpoints in a Phase 2b vitiligo trial, leading to its termination. VYNE is now seeking a development partner for repibresib [1].
VYNE has implemented cost reductions that are expected to extend its cash runway into the first half of 2027, providing additional flexibility during this period. The company is actively evaluating opportunities to enhance the value of its pipeline programs [1].
References
[1] https://www.stocktitan.net/news/VYNE/vyne-therapeutics-reports-2025-second-quarter-financial-results-and-5mmdapji5gol.html
[2] https://www.globenewswire.com/news-release/2025/08/14/3133434/0/en/VYNE-Therapeutics-Reports-2025-Second-Quarter-Financial-Results-and-Provides-Business-Update.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet